CombiMatrix Corp, an Irvine, Calif-based molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, has entered into a contractual agreement for coverage of its diagnostic laboratory services with FedMed, a national provider network and healthcare financial services organization.
FedMed is based in Gaithersburg, Md, and has a preferred provider network that includes more than 550,000 physicians, 4,000 hospitals, and 60,000 ancillary care providers nationwide. FedMed’s objective is to provide significant measurable benefits to providers not available from other provider networks and managed care organizations. More than 40 million people have access to FedMed’s preferred provider network.
CombiMatrix offers comprehensive testing services for the detection of genetic abnormalities at the DNA level, beyond what can be identified through traditional methodologies. The company performs genetic testing utilizing advanced technologies, including microarray, FISH, PCR, and G-Band chromosome analyses.
The contract with FedMed provides its members access to CombiMatrix’s suite of molecular diagnostic solutions and comprehensive clinical support specializing in prenatal, miscarriage, and pediatric healthcare.
“We believe this contract is another validation of our strategy to partner with nationally known and respected provider networks like FedMed, which connects us to a large group of physicians, hospitals, and ancillary care providers,” said CombiMatrix CEO Mark McDonough. “It also underscores the notion that physicians better understand the value of the services we offer their patients, particularly chromosomal microarray analysis or CMA. We expect the recent endorsement of CMA from the American College of Obstetricians and Gynecologists to continue to drive interest in our services.”
For further information visit FedMed or CombiMatrix.
